Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?

Autor:	Elsayed M; Internal Medicine, University of Missouri Kansas City School of Medicine, Kansas City, USA., Harry S; Hematology/Oncology, Saint Francis Cancer Center Warren Clinic, Tulsa, USA., Nanua S; Oncology, Saint Luke's Cancer Institute, University of Missouri Kansas City, Kansas City, USA., Zaidi S; Oncology, University of Kansas School of Medicine, Kansas City, USA., Habib MH; Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA., Raza S; Oncology, Saint Luke's Cancer Institute, University of Missouri Kansas City, Kansas City, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Jul 06; Vol. 14 (7), pp. e26619. Date of Electronic Publication: 2022 Jul 06 (Print Publication: 2022).
DOI:	10.7759/cureus.26619
Abstrakt:	Atypical chronic myeloid leukemia (aCML) is a rare disease that is currently classified under the myelodysplastic (MDS)/myeloproliferative neoplasm (MPN) disease spectrum. MDS/MPN diseases are characterized by the absence of the Philadelphia (Ph) chromosome and the overlap between bone marrow fibrosis and dysplastic features. The Ph chromosome, resulting from BCR-ABL1 translocation, helps to distinguish aCML from chronic myeloid leukemia (CML). The currently reported incidence of aCML is imprecise because aCML is diagnosed primarily based on morphological features and other unspecified laboratory findings, and there is an especially high chance of under-diagnosis of aCML and other MDS/MPN diseases. Recent advances in next-generation sequencing (NGS) have allowed a greater understanding of the nature of aCML, providing better opportunities to achieve higher diagnostic accuracy and for the use of more targeted treatment to achieve better outcomes. Herein, we present a case of a 68-year-old woman who came to our hospital complaining of shortness of breath, fatigue, and weakness, who was found to have significantly increased leukocytosis, hepatosplenomegaly, and was negative for the Ph chromosome. Further investigations with NGS revealed mutations in ASXL1, GATA2, NRAS, and SRSF2 but not CSF3R. In addition to this, peripheral smear and bone marrow aspiration findings were suggestive of aCML based on specific morphological findings. Since the patient was ineligible for a stem cell transplant (SCT), symptomatic treatment was started with cell transfusion; however, the patient continued to have symptomatic anemia that required multiple transfusions. A trial with trametinib, a mitogen-activated protein kinase kinase (MEK) inhibitor, was later started as a targeted therapy based on one of her genetic mutations. Interestingly, the patient's blood counts stabilized, she reported feeling better, and she did not need any blood transfusions for four consecutive months during treatment with trametinib. Unfortunately, our patient later died from sepsis resulting from secondary infections. In light of the significant advancements in NGS, clinicians should always consider utilizing it as a helpful tool to not only establish a rare diagnosis of aCML but also to offer the best available targeted therapy when applicable. This might alleviate the burden associated with the poor prognosis of aCML. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Elsayed et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu